Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player

SIMPLE SUMMARY: While radiotherapy remains a key therapy for many cancers, in recent years, DNA repair inhibitors, particularly PARP inhibitors, and immunotherapy, specifically immune-checkpoint inhibitors, have progressively shown great therapeutic potential in several experimental and clinical set...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosado, Maria Manuela, Pioli, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954050/
https://www.ncbi.nlm.nih.gov/pubmed/36831435
http://dx.doi.org/10.3390/cancers15041093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954050/
https://www.ncbi.nlm.nih.gov/pubmed/36831435
http://dx.doi.org/10.3390/cancers15041093

Ejemplares similares